Amgen's director of value, access and policy, Ian Noble, says Australia needs a clear vision to address the 820-day medicines 'access gap'.He says Amgen was disappointed with the report of the recent parliamentary inquiry and that a vision and agreed principles are essential to ensuring the pending health technology assessment review avoids becoming just another negotiation and actually delivers for Australian patients.